The Vox Markets Podcast / Neil Clark of Destiny Pharma discusses XF-73’s significant Phase 2 data published in a peer reviewed journal & potential upside

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.